Phillip W. Berman
Papers
3
Total Citations
26
H-Index
2
About
Phillip W. Berman is a leading researcher in HIV vaccine development, with a primary focus on overcoming the critical manufacturing challenges that have hindered the production of effective immunogens. His work centers on the expression of envelope glycoproteins (Envs), the key targets for neutralizing antibodies, in Chinese Hamster Ovary (CHO) cell lines. Berman’s major contribution lies in pioneering robotic selection technologies to rapidly develop stable, high-yield CHO cell lines, addressing the persistent problem of Env yields being 10-100 fold lower than other pharmaceutical glycoproteins. His most cited work (21 citations) details this robotic platform, which dramatically accelerates the creation of stable cell lines for HIV vaccine production. Further, Berman has developed specialized MGAT1- CHO cell lines that produce clade C gp120 with significantly improved binding to broadly neutralizing antibodies, a crucial step toward a globally effective vaccine. His research is directly motivated by the urgent need for a safe and effective vaccine, particularly in Sub-Saharan Africa, building upon the partial success of the RV144 trial. Through these innovations, Berman is removing a key bottleneck in the path to an affordable, scalable HIV vaccine.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3